Yohimbine: taking the brake off the fat cell

Yohimbine is an alkaloid from the bark of Pausinystalia johimbe, and the molecule that matters is an antagonist at the alpha-2 adrenergic receptor. A fat cell listens to two opposing voices from the same nerve. Beta-2, the receptor clenbuterol occupies, raises cyclic AMP and lets hormone-sensitive lipase open the droplet. Alpha-2 is coupled to Gi. It lowers cyclic AMP and holds the lid on. Human subcutaneous fat, especially on the hips and the lower abdomen, is rich in alpha-2. That is why those pads stay quiet when you are only slightly stressed or slightly hungry: the brake is bigger than the accelerator. Yohimbine sits in the alpha-2 pocket and does not switch it on. The catecholamine that was already there can then use the beta receptor without the Gi hand cancelling it. Lafontan and Galitzky mapped this on human fat cells decades ago. The drug is not inventing lipolysis. It is taking the foot off a brake the fat cell was using.

In short. Fat cells have a brake called alpha-2. Yohimbine blocks that brake so adrenaline can open the fat store. It does not light a new fire. It stops the lid being held down.

Insulin is the other lid, and it is why the gym rumour says fasted. Insulin turns on PDE3B, a phosphodiesterase that destroys cyclic AMP in the fat cell, and it also pushes glucose in so the cell would rather store than release. A high insulin level can sit on top of an alpha-2 antagonist and the droplet still will not open. That is a mechanism, not a meal plan. The same alpha-2 receptors sit on sympathetic nerve endings, where they normally restrain how much noradrenaline the nerve dumps. Block them and the nerve releases more. Blood pressure rises. Heart rate rises. The hands can shake for a different reason than clenbuterol. People feel anxious, sweaty, and too awake, because the same antagonist is in the brain, where alpha-2 receptors were holding the sympathetic system down. Yohimbine hydrochloride is a defined molecule. The bark is a mixture, and the amount of the alkaloid in a capsule of bark is a guess. Those are not the same product.

In short. If insulin is high, the fat cell still will not open. Blocking alpha-2 also lets the nerves dump more adrenaline, so the pulse, the blood pressure and the anxiety go up. The pure chemical and the bark are not the same thing.

Clenbuterol is an agonist. It sits on beta-2 and turns the accelerator on for about a day, including on the heart. Yohimbine is an antagonist. It sits on alpha-2 and takes a brake off, for a few hours, and the heart still hears the extra noradrenaline. Stacking them stacks two ways of raising cyclic AMP in a fat cell and two reasons for a rate to climb. Neither binds the androgen receptor. Neither stops LH falling if an androgen is in the picture. Neither adds a sarcomere. A study can show a little more fat leaving in lean, already-trained people when the drug is in and the calories are already short. That is a small shift in who wins the cyclic AMP argument, measured on a body that was going to lose fat anyway. It is not a pad of fat that has a postcode the drug can read. Alpha-2 richness is real. A drug that only empties one patch while you eat through the rest is still arithmetic.

In short. Clenbuterol presses the accelerator. Yohimbine takes a brake off. Using both leans on the heart twice. Neither one chooses a patch of fat by magic, and neither one builds muscle.

The off switches are ordinary. The drug leaves, alpha-2 works again, and the lid goes back on if insulin is up or the catecholamines have gone home. Tolerance here is not the beta-arrestin story clenbuterol tells, because yohimbine is not turning the receptor on. The cost that shows up in people is the sympathetic one: pressure, panic, a person who already runs anxious getting a worse afternoon. An MAOI antidepressant plus something that raises noradrenaline is the old dangerous combination, because the enzyme that was clearing the transmitter is already occupied. This page is only that brake. Read the clenbuterol page for the accelerator. Read the fibre pages for what actually adds myosin.

In short. When the drug wears off, the brake works again. The bill people actually meet is a faster pulse and more anxiety, not a new muscle.

Alpha-2 is three genes, ADRA2A, ADRA2B and ADRA2C, not one blob. The fat-cell brake and a great deal of the brain brake are alpha-2A. Alpha-2B and alpha-2C have their own posts, including on vessels and on some nerve endings, which is why a drug that is only 'alpha-2 selective' still moves blood pressure in more than one way. On the fat cell the receptor is Gi. The Gi subunit turns adenylyl cyclase down, cyclic AMP falls, and protein kinase A never gets to phosphorylate perilipin-1 or hormone-sensitive lipase. The protein coat stays on the droplet. The scissors never arrive. Yohimbine occupying that pocket does not phosphorylate the tail the way an agonist would, so this is not the beta-arrestin withdrawal clenbuterol uses. The brake simply works again when the antagonist leaves. Human white fat uses beta-1 and beta-2 as the accelerator. Beta-3, the receptor the rodent papers got excited about, is a quiet voice in human subcutaneous fat. A drug written as if you were a mouse is talking to a receptor you barely have.

In short. The brake is a named receptor, alpha-2A, that stops the kinase from opening the droplet. Human fat uses beta-1 and beta-2 to open it. The mouse receptor, beta-3, is barely there.

The parent molecule does not stay long. Clearance is on the order of an hour, and the liver enzyme CYP2D6 turns it into 11-hydroxyyohimbine, which is still an alpha-2 antagonist. A slow version of that enzyme keeps both molecules in the blood longer. A fast version clears them and wonders why the capsule did nothing. That is the same gene that handles a long list of other drugs, which is why two people can take the same milligram and have different afternoons. The bark adds further alkaloids the hydrochloride does not have, so a bad afternoon on bark is not a clean alpha-2A experiment. None of this selects a fat cell by postcode. A pad that is rich in alpha-2 will respond more when catecholamines are up and insulin is down. A pad that is mostly beta receptors was already going to open. Eating through either of them rebuilds the droplet, because the fatty acids that left are still calories.

In short. The drug lasts about an hour, and the liver turns it into a second blocker that also works. People with a slow liver enzyme keep both for longer. The fat that leaves is still a calorie you can put back.